Ascletis reports positive phase Ib results for oral GLP-1R agonist ASC30 at EASD 2025
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The inspection was carried out between May 26, 2025 and May 31, 2025
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Subscribe To Our Newsletter & Stay Updated